Momentum Stock: Par Pharmaceutical Companies (PRX)

Par Pharmaceutical Companies, Inc. (PRX) continues to pressure its multi-year high just above $29 on rising estimates and a compelling valuation. This Zacks #1 rank stock will take a four-quarter, average-earnings surprise of 27% into its early, August Q2 results. Company Description Par Pharmaceutical Companies, Inc, through its subsidiaries, develops and manufactures generic [...]